Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Accumulated Expenses (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Accumulated Expenses readings, the most recent being $2.3 million for Q1 2026.

  • Quarterly Accumulated Expenses fell 23.35% to $2.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Mar 2026, down 23.35% year-over-year, with the annual reading at $3.5 million for FY2025, 18.45% down from the prior year.
  • Accumulated Expenses hit $2.3 million in Q1 2026 for DiaMedica Therapeutics, down from $3.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.3 million in Q4 2024 and bottomed at $161000.0 in Q1 2023.
  • Average Accumulated Expenses over 5 years is $1.8 million, with a median of $1.4 million recorded in 2022.
  • The largest annual shift saw Accumulated Expenses tumbled 83.35% in 2023 before it surged 1027.33% in 2024.
  • DiaMedica Therapeutics' Accumulated Expenses stood at $1.4 million in 2022, then crashed by 43.88% to $766000.0 in 2023, then soared by 467.49% to $4.3 million in 2024, then fell by 18.45% to $3.5 million in 2025, then tumbled by 33.99% to $2.3 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Accumulated Expenses are $2.3 million (Q1 2026), $3.5 million (Q4 2025), and $920000.0 (Q3 2025).